Indication intelligence, analysis and sector perception

Fate Therapeutics (FATE) exclusively licensed patent for off-the-shelf adoptive immunotherapy

October 28, 2015 10:27am

Was issued for the generation of induced pluripotent cells … HOLD at this pricing!

FATE reported the USPTO has issued it a US Patent <owned by the Whitehead Institute for Biomedical Research. The compositions described in the patent are foundational to the generation of induced pluripotent cells, which are a source of cells offering unique potential for off-the-shelf adoptive immunotherapy.

The Bottom Line: This novel induced pluripotent cell approach to cancer immunotherapy combines genetic engineering with rapid and efficient generation of immune cells designed to enable the unlimited production of engineered T cells and NK cells in a consistent, scalable and efficient manner.

The newly issued U.S. patent, which is owned by the Whitehead Institute for Biomedical Research and licensed exclusively to FATE for all therapeutic purposes, provides broad protection for cell compositions expressing a sufficient amount of octamer-binding transcription factor 4 (Oct4) to enable pluripotency.

The production of Oct4 protein within a cell is a critical requirement to consistently and efficiently induce pluripotency. FATE is utilizing its novel platform to engineer the immunological properties of pluripotent cells, creating a … continual source for the generation of engineered T- and NK-cell immunotherapeutics.

FATE closed at $3.57 and is UP +$0.19 or +5.32% to $3.76 which was also mentioned in our pre-open posting as a BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.